ScreenCell® Technology

A circulating tumor cells test for capture CTC from blood sample.

The liquid biopsy technology dedicated to the detection of circulating tumor cells

The ScreenCell technology is a versatile circulating tumor cells test designed for the non-invasive detection of CTCs from a simple blood draw in patients with solid cancers.

The ScreenCell technology is available in seven single-use kits dedicated to the detection of circulating tumor cells. Each kit is designed for distinct and specific applications.

The strengths of our circulating tumor cells test

The ScreenCell® technology offers researchers a versatile and efficient solution to isolate circulating tumor cells (CTCs), providing a wide range of possibilities for downstream analyses and applications.

> 0 %

Recovery rate

EpCAM-Independent

< 0 min

Fast filtration time

Single-use device

Easy-to-use

Cost-effective

It is the researchers who speak about it best

“Overall, the ScreenCell® technique exhibited higher sensitivity.”

Doi : 10.1371/journal.pone.0237308

“CTC were detected by either approach; however, with varying positivity rates: N method 36.4%, ScreenCell® 100%, and PCR 80.5%. All methods revealed a positive correlation of CTC presence and higher tumor burden, which was most striking using the ScreenCell® device.”

Doi : 10.3390/cancers12092643

“Out of the four commercially available CTC enrichment methods […] we found that the ScreenCell® method offered the most potential for translational application in the clinical setting”

Doi : 10.3389/fneur.2024.1358531

Downstream analyses available with our CTC test

Discover a multitude of downstream analyses achievable with our circulating tumor cell test and choose the one you need across our three areas of expertise: Cytology, Molecular Biology and Cell Culture.

Looking for a simple method for CTC isolation?

You’ve come to the right place!
Fill in the fields below and we’ll take care of the rest.